Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery

Rossella Libè, Paola Silvia Morpurgo, Vincenzo Cappiello, Antonia Maffini, Sara Bondioni, Marco Locatelli, Mario Zavanone, Paolo Beck-Peccoz, Anna Spada

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background Ghrelin, an endogenous ligand of the GH secretagogue receptor that exerts orexigenic activity, is negatively correlated with body mass index (BMI) and insulin resistance. Conversely, low levels of adiponectin (ApN), a circulating adipocytokine with antidiabetic, antiatherogenic and anti-inflammatory properties, have been found in several insulin-resistant conditions. Although Cushing's syndrome causes several metabolic and hormonal changes leading to insulin resistance and central obesity, few data concerning the impact of glucocorticoid excess on ghrelin and ApN levels are so far available. Design We evaluated ghrelin and ApN levels in 14 women (age ± SE 39.5 ± 3.9 years, BMI ± SE 25.8 ± 1.4 kg/m2) with Cushing's disease (CD) at baseline and after successful transsphenoidal surgery (TSS) and in 14 age- and BMI-matched healthy women. Results Despite similar levels of fasting glucose, insulin, homeostatic model assessment-estimated insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) values, patients with CD had ghrelin levels lower than controls (117.8 ± 21.5 vs. 269.6 ± 51.4 pmol/l, P <0.01), and ghrelin levels did not correlate with ACTH, cortisol, androgen and GH levels. Patients and controls showed similar ApN levels (11.1 ± 1.6 vs. 11.5 ± 2.0 mg/l), which correlated negatively with insulin, HOMA-IR and BMI and positively with QUICKI and high density lipoprotein (HDL)-cholesterol only in controls. At 10.2 ± 0.7 months after successful TSS, patients showed a significant increase in ghrelin levels compared to pretreatment values (342.5 ± 25.6 vs. 117.8 ± 21.5 pmol/l, P <0.005) along with significant modifications in BMI, insulin, HOMA-IR and HDL-cholesterol and no change in ApN levels. In two patients tested on days 2-4 after TSS, no modification in ghrelin and ApN levels was observed, despite a dramatic reduction in cortisol levels. Conclusion Cortisol excess did not directly affect ghrelin and ApN levels in patients with CD. The observation that ghrelin levels were low during the active phase of CD and increased after recovery suggests that glucocorticoids may influence ghrelin levels indirectly by modulating adiposity and metabolic signals over the long term.

Original languageEnglish
Pages (from-to)30-36
Number of pages7
JournalClinical Endocrinology
Volume62
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Pituitary ACTH Hypersecretion
Ghrelin
Adiponectin
Insulin Resistance
Body Mass Index
Insulin
Hydrocortisone
HDL Cholesterol
Glucocorticoids
Adipokines
Abdominal Obesity
Cushing Syndrome
Adiposity
Hypoglycemic Agents
Adrenocorticotropic Hormone
Androgens
Fasting
Anti-Inflammatory Agents
Ligands
Glucose

ASJC Scopus subject areas

  • Endocrinology

Cite this

Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. / Libè, Rossella; Morpurgo, Paola Silvia; Cappiello, Vincenzo; Maffini, Antonia; Bondioni, Sara; Locatelli, Marco; Zavanone, Mario; Beck-Peccoz, Paolo; Spada, Anna.

In: Clinical Endocrinology, Vol. 62, No. 1, 01.2005, p. 30-36.

Research output: Contribution to journalArticle

Libè, R, Morpurgo, PS, Cappiello, V, Maffini, A, Bondioni, S, Locatelli, M, Zavanone, M, Beck-Peccoz, P & Spada, A 2005, 'Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery', Clinical Endocrinology, vol. 62, no. 1, pp. 30-36. https://doi.org/10.1111/j.1365-2265.2004.02169.x
Libè, Rossella ; Morpurgo, Paola Silvia ; Cappiello, Vincenzo ; Maffini, Antonia ; Bondioni, Sara ; Locatelli, Marco ; Zavanone, Mario ; Beck-Peccoz, Paolo ; Spada, Anna. / Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. In: Clinical Endocrinology. 2005 ; Vol. 62, No. 1. pp. 30-36.
@article{eee4f71121d049c8b5495df2e1855ad0,
title = "Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery",
abstract = "Background Ghrelin, an endogenous ligand of the GH secretagogue receptor that exerts orexigenic activity, is negatively correlated with body mass index (BMI) and insulin resistance. Conversely, low levels of adiponectin (ApN), a circulating adipocytokine with antidiabetic, antiatherogenic and anti-inflammatory properties, have been found in several insulin-resistant conditions. Although Cushing's syndrome causes several metabolic and hormonal changes leading to insulin resistance and central obesity, few data concerning the impact of glucocorticoid excess on ghrelin and ApN levels are so far available. Design We evaluated ghrelin and ApN levels in 14 women (age ± SE 39.5 ± 3.9 years, BMI ± SE 25.8 ± 1.4 kg/m2) with Cushing's disease (CD) at baseline and after successful transsphenoidal surgery (TSS) and in 14 age- and BMI-matched healthy women. Results Despite similar levels of fasting glucose, insulin, homeostatic model assessment-estimated insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) values, patients with CD had ghrelin levels lower than controls (117.8 ± 21.5 vs. 269.6 ± 51.4 pmol/l, P <0.01), and ghrelin levels did not correlate with ACTH, cortisol, androgen and GH levels. Patients and controls showed similar ApN levels (11.1 ± 1.6 vs. 11.5 ± 2.0 mg/l), which correlated negatively with insulin, HOMA-IR and BMI and positively with QUICKI and high density lipoprotein (HDL)-cholesterol only in controls. At 10.2 ± 0.7 months after successful TSS, patients showed a significant increase in ghrelin levels compared to pretreatment values (342.5 ± 25.6 vs. 117.8 ± 21.5 pmol/l, P <0.005) along with significant modifications in BMI, insulin, HOMA-IR and HDL-cholesterol and no change in ApN levels. In two patients tested on days 2-4 after TSS, no modification in ghrelin and ApN levels was observed, despite a dramatic reduction in cortisol levels. Conclusion Cortisol excess did not directly affect ghrelin and ApN levels in patients with CD. The observation that ghrelin levels were low during the active phase of CD and increased after recovery suggests that glucocorticoids may influence ghrelin levels indirectly by modulating adiposity and metabolic signals over the long term.",
author = "Rossella Lib{\`e} and Morpurgo, {Paola Silvia} and Vincenzo Cappiello and Antonia Maffini and Sara Bondioni and Marco Locatelli and Mario Zavanone and Paolo Beck-Peccoz and Anna Spada",
year = "2005",
month = "1",
doi = "10.1111/j.1365-2265.2004.02169.x",
language = "English",
volume = "62",
pages = "30--36",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery

AU - Libè, Rossella

AU - Morpurgo, Paola Silvia

AU - Cappiello, Vincenzo

AU - Maffini, Antonia

AU - Bondioni, Sara

AU - Locatelli, Marco

AU - Zavanone, Mario

AU - Beck-Peccoz, Paolo

AU - Spada, Anna

PY - 2005/1

Y1 - 2005/1

N2 - Background Ghrelin, an endogenous ligand of the GH secretagogue receptor that exerts orexigenic activity, is negatively correlated with body mass index (BMI) and insulin resistance. Conversely, low levels of adiponectin (ApN), a circulating adipocytokine with antidiabetic, antiatherogenic and anti-inflammatory properties, have been found in several insulin-resistant conditions. Although Cushing's syndrome causes several metabolic and hormonal changes leading to insulin resistance and central obesity, few data concerning the impact of glucocorticoid excess on ghrelin and ApN levels are so far available. Design We evaluated ghrelin and ApN levels in 14 women (age ± SE 39.5 ± 3.9 years, BMI ± SE 25.8 ± 1.4 kg/m2) with Cushing's disease (CD) at baseline and after successful transsphenoidal surgery (TSS) and in 14 age- and BMI-matched healthy women. Results Despite similar levels of fasting glucose, insulin, homeostatic model assessment-estimated insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) values, patients with CD had ghrelin levels lower than controls (117.8 ± 21.5 vs. 269.6 ± 51.4 pmol/l, P <0.01), and ghrelin levels did not correlate with ACTH, cortisol, androgen and GH levels. Patients and controls showed similar ApN levels (11.1 ± 1.6 vs. 11.5 ± 2.0 mg/l), which correlated negatively with insulin, HOMA-IR and BMI and positively with QUICKI and high density lipoprotein (HDL)-cholesterol only in controls. At 10.2 ± 0.7 months after successful TSS, patients showed a significant increase in ghrelin levels compared to pretreatment values (342.5 ± 25.6 vs. 117.8 ± 21.5 pmol/l, P <0.005) along with significant modifications in BMI, insulin, HOMA-IR and HDL-cholesterol and no change in ApN levels. In two patients tested on days 2-4 after TSS, no modification in ghrelin and ApN levels was observed, despite a dramatic reduction in cortisol levels. Conclusion Cortisol excess did not directly affect ghrelin and ApN levels in patients with CD. The observation that ghrelin levels were low during the active phase of CD and increased after recovery suggests that glucocorticoids may influence ghrelin levels indirectly by modulating adiposity and metabolic signals over the long term.

AB - Background Ghrelin, an endogenous ligand of the GH secretagogue receptor that exerts orexigenic activity, is negatively correlated with body mass index (BMI) and insulin resistance. Conversely, low levels of adiponectin (ApN), a circulating adipocytokine with antidiabetic, antiatherogenic and anti-inflammatory properties, have been found in several insulin-resistant conditions. Although Cushing's syndrome causes several metabolic and hormonal changes leading to insulin resistance and central obesity, few data concerning the impact of glucocorticoid excess on ghrelin and ApN levels are so far available. Design We evaluated ghrelin and ApN levels in 14 women (age ± SE 39.5 ± 3.9 years, BMI ± SE 25.8 ± 1.4 kg/m2) with Cushing's disease (CD) at baseline and after successful transsphenoidal surgery (TSS) and in 14 age- and BMI-matched healthy women. Results Despite similar levels of fasting glucose, insulin, homeostatic model assessment-estimated insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) values, patients with CD had ghrelin levels lower than controls (117.8 ± 21.5 vs. 269.6 ± 51.4 pmol/l, P <0.01), and ghrelin levels did not correlate with ACTH, cortisol, androgen and GH levels. Patients and controls showed similar ApN levels (11.1 ± 1.6 vs. 11.5 ± 2.0 mg/l), which correlated negatively with insulin, HOMA-IR and BMI and positively with QUICKI and high density lipoprotein (HDL)-cholesterol only in controls. At 10.2 ± 0.7 months after successful TSS, patients showed a significant increase in ghrelin levels compared to pretreatment values (342.5 ± 25.6 vs. 117.8 ± 21.5 pmol/l, P <0.005) along with significant modifications in BMI, insulin, HOMA-IR and HDL-cholesterol and no change in ApN levels. In two patients tested on days 2-4 after TSS, no modification in ghrelin and ApN levels was observed, despite a dramatic reduction in cortisol levels. Conclusion Cortisol excess did not directly affect ghrelin and ApN levels in patients with CD. The observation that ghrelin levels were low during the active phase of CD and increased after recovery suggests that glucocorticoids may influence ghrelin levels indirectly by modulating adiposity and metabolic signals over the long term.

UR - http://www.scopus.com/inward/record.url?scp=12944297625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944297625&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2004.02169.x

DO - 10.1111/j.1365-2265.2004.02169.x

M3 - Article

C2 - 15638867

AN - SCOPUS:12944297625

VL - 62

SP - 30

EP - 36

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 1

ER -